ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today ...
Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease, to be presented at the 2026 AD/PD™ Conference· Data evaluated safety, tolerability, ...
New data show that blarcamesine completely rescued impaired motor functionBiomarker of nerve fiber density of dopaminergic nerve cells indicating ...
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such ...
Post hoc analyses of two Phase 2 trials examine the potential benefits of solengepras, a once-daily, oral, non-dopaminergic ...
Session: Oral Poster Presentation – Guided Poster TourSession Date: Saturday, May 10, 2025Session Time: 8:00-9:00 a.m. EST About GT-02287Gain Therapeutics’ lead drug candidate, GT-02287, is in ...
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that an abstract from its SUNRISE-PD study evaluating its lead candidate bezisterim (NE3107) for Parkinson’s disease has been accepted for presentation ...
NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today ...
Where drinking water comes from and what it contains may affect Parkinson's disease risk, a recent study suggests.
Gain Therapeutics, Inc., a clinical-stage biotechnology company, announced that it will present its lead drug candidate, GT-02287, at the International Association of Parkinsonism and Related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results